
AstraZeneca lung cancer drug proves able to shrink EGFR mutation-positive tumours
pharmafile | October 17, 2017 | News story | Manufacturing and Production, Research and Development | AstraZeneca, Cancer, Chi-Med, lung cancer, pharma, savolitinib
AstraZeneca and its partner Hutchison China MedTech, also known as Chi-Med, have announced positive data for savolitinib in combination with either AstraZeneca’s Tagrisso or Iressa in shrinking the tumours of lung cancer patients whose disease had progressed after treatment with approved drugs.
In one study, savolitinib produced a partial response in 28% of participants with EGFR-mutated advanced non-small cell lung cancer who had previously been given Tagrisso, while it generated a 31% response in those previously treated with Iressa. Partial response is defined as a reduction in size in measurable tumours by at least 30%
Savolitinib works by targeting c-MET, an enzyme which acts abnormally in many tumours, limiting their ability to develop resistance mechanisms – a trait which often foils the attempts of drugs like Tagrisso and Iressa in EGFR-mutated cancers. When these therapies are used in combination, this can be circumvented.
“We are committed to developing innovative medicines to overcome the key drivers of cancer mechanisms of resistance and are strategically focused on developing effective combinations. The latest results for savolitinib in combination with osimertinib and gefitinib support our approach in collaboration with Chi-Med,” said Susan Galbraith, head of Oncology Research & Early Development at AstraZeneca.
Matt Fellows
Related Content

AstraZeneca’s Trixeo approved in EU for asthma
AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a …

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …





